Eyenovia Inc
EYEN15.820USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
44.78MMarket Cap
LossP/E TTM
More Details of Eyenovia Inc Company
Eyenovia, Inc. is a commercial-stage ophthalmic pharmaceutical technology company developing a pipeline of microdose array print therapeutics based on its Optejet platform. It is focused on the commercialization of Mydcombi (tropicamide+phenylephrine ophthalmic spray) for mydriasis, as well as clobetasol propionate ophthalmic suspension 0.05% to reduce pain and inflammation following ocular surgery. Its product line includes Mydcombi, clobetasol propionate, and therapeutic programs, MicroPine and MicroLine. Mydcombi is its fixed combination formulation of tropicamide-phenylephrine for inducing mydriasis for diagnostic procedures and in conditions where short-term pupil dilation is desired. MicroPine is its topical therapy for the treatment of progressive myopia, a disease associated with pathologic axial elongation of the eye and sclero-retinal stretching. MicroLine is its investigational pharmacologic treatment for presbyopia, a non-preventable, age-related hardening of the lens.
Eyenovia Inc Info
Ticker SymbolEYEN
Company nameHyperion DeFi Inc
IPO dateJan 25, 2018
CEOMr. Michael M. Rowe
Number of employees13
Security typeOrdinary Share
Fiscal year-endJan 25
Address295 Madison Ave Ste 2400
CityNEW YORK
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code10017
Phone18137669539
Websitehttps://eyenovia.com/
Ticker SymbolEYEN
IPO dateJan 25, 2018
CEOMr. Michael M. Rowe
Company Executives of Eyenovia Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Hyunsu Jung
Mr. Hyunsu Jung
Interim Chief Executive Officer, Principal Financial Officer, Treasurer, Company Secretary
Interim Chief Executive Officer, Principal Financial Officer, Treasurer, Company Secretary
1.50M
+200.00%
Mr. David Knox
Mr. David Knox
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
300.00K
--
Dr. Ellen R. Strahlman, M.D.
Dr. Ellen R. Strahlman, M.D.
Independent Director
Independent Director
56.71K
+745.60%
Ms. Rachel Jacobson
Ms. Rachel Jacobson
Independent Director
Independent Director
56.30K
+793.52%
Mr. Happy David Walters
Mr. Happy David Walters
Director
Director
50.00K
--
Mr. Eric Ribner
Mr. Eric Ribner
Investor Relations
Investor Relations
--
--
Mr. Michael Geltzeiler
Mr. Michael Geltzeiler
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Hyunsu Jung
Mr. Hyunsu Jung
Interim Chief Executive Officer, Principal Financial Officer, Treasurer, Company Secretary
Interim Chief Executive Officer, Principal Financial Officer, Treasurer, Company Secretary
1.50M
+200.00%
Mr. David Knox
Mr. David Knox
Chief Financial Officer, Treasurer, Secretary
Chief Financial Officer, Treasurer, Secretary
300.00K
--
Dr. Ellen R. Strahlman, M.D.
Dr. Ellen R. Strahlman, M.D.
Independent Director
Independent Director
56.71K
+745.60%
Ms. Rachel Jacobson
Ms. Rachel Jacobson
Independent Director
Independent Director
56.30K
+793.52%
Mr. Happy David Walters
Mr. Happy David Walters
Director
Director
50.00K
--
Mr. Eric Ribner
Mr. Eric Ribner
Investor Relations
Investor Relations
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Nov 20
Updated: Thu, Nov 20
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Jung (Hyunsu)
18.35%
Forsakringsaktiebolaget Skadinviska Enskilda
3.92%
Knox (David R)
3.67%
Avenue Capital Group
2.94%
Walters (Happy David)
1.37%
Other
69.75%
Shareholders
Shareholders
Proportion
Jung (Hyunsu)
18.35%
Forsakringsaktiebolaget Skadinviska Enskilda
3.92%
Knox (David R)
3.67%
Avenue Capital Group
2.94%
Walters (Happy David)
1.37%
Other
69.75%
Shareholder Types
Shareholders
Proportion
Individual Investor
25.17%
Investment Advisor/Hedge Fund
4.07%
Corporation
3.92%
Investment Advisor
3.54%
Research Firm
1.05%
Hedge Fund
0.33%
Other
61.92%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
130
566.56K
8.14%
+152.59K
2025Q2
143
1.30M
23.22%
+964.95K
2025Q1
143
295.59K
7.15%
-40.48K
2024Q4
145
87.40K
4.18%
-230.58K
2024Q3
143
274.49K
30.78%
+4.44K
2024Q2
142
255.79K
39.17%
+31.25K
2024Q1
131
203.15K
36.02%
-59.46K
2023Q4
121
244.77K
45.33%
+8.04K
2023Q3
122
223.92K
43.30%
+34.30K
2023Q2
116
185.43K
39.56%
+8.82K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Jung (Hyunsu)
1.50M
21.55%
+1.00M
+200.00%
Aug 18, 2025
Knox (David R)
300.00K
4.31%
+300.00K
--
Sep 29, 2025
Avenue Capital Group
240.12K
3.45%
+240.12K
--
Sep 17, 2025
Walters (Happy David)
50.00K
0.72%
+50.00K
--
Sep 08, 2025
Geltzeiler (Michael S)
58.02K
0.83%
+50.00K
+623.83%
Aug 18, 2025
Strahlman (Ellen R)
56.71K
0.81%
+50.00K
+745.60%
Aug 18, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Proshares Ultra Russell 2000
0%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
ProShares UltraPro Russell2000
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Russell 2000 ETF
0%
Proshares Ultra Russell 2000
Proportion0%
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Micro-Cap ETF
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 Covered Call ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jan 15, 2025
Merger
80→1
Jan 15, 2025
Merger
80→1
Jan 15, 2025
Merger
80→1
Jan 15, 2025
Merger
80→1
Date
Type
Ratio
Jan 15, 2025
Merger
80→1
Jan 15, 2025
Merger
80→1
Jan 15, 2025
Merger
80→1
Jan 15, 2025
Merger
80→1
FAQs
Who are the top five shareholders of Eyenovia Inc?
The top five shareholders of Eyenovia Inc are:
Jung (Hyunsu) holds 1.50M shares, accounting for 21.55% of the total shares.
Knox (David R) holds 300.00K shares, accounting for 4.31% of the total shares.
Avenue Capital Group holds 240.12K shares, accounting for 3.45% of the total shares.
Walters (Happy David) holds 50.00K shares, accounting for 0.72% of the total shares.
Geltzeiler (Michael S) holds 58.02K shares, accounting for 0.83% of the total shares.
Jung (Hyunsu) holds 1.50M shares, accounting for 21.55% of the total shares.
Knox (David R) holds 300.00K shares, accounting for 4.31% of the total shares.
Avenue Capital Group holds 240.12K shares, accounting for 3.45% of the total shares.
Walters (Happy David) holds 50.00K shares, accounting for 0.72% of the total shares.
Geltzeiler (Michael S) holds 58.02K shares, accounting for 0.83% of the total shares.
What are the top three shareholder types of Eyenovia Inc?
The top three shareholder types of Eyenovia Inc are:
Jung (Hyunsu)
Forsakringsaktiebolaget Skadinviska Enskilda
Knox (David R)
Jung (Hyunsu)
Forsakringsaktiebolaget Skadinviska Enskilda
Knox (David R)
How many institutions hold shares of Eyenovia Inc (EYEN)?
As of 2025Q3, 130 institutions hold shares of Eyenovia Inc, with a combined market value of approximately 566.56K, accounting for 8.14% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -15.08%.
What is the biggest source of revenue for Eyenovia Inc?
In --, the -- business generated the highest revenue for Eyenovia Inc, amounting to -- and accounting for --% of total revenue.
